scispace - formally typeset
Open AccessJournal ArticleDOI

Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19.

Reads0
Chats0
TLDR
The currently unfolding coronavirus pandemic threatens health systems and economies worldwide and needs to be considered as a global public health emergency, not a medical emergency.
Abstract
The currently unfolding coronavirus pandemic threatens health systems and economies worldwide.….

read more

Content maybe subject to copyright    Report

Citations
More filters

SARS-CoV-2

Jeremy Luban
Journal ArticleDOI

Coronavirus biology and replication: implications for SARS-CoV-2.

TL;DR: The first discoveries that shape the current understanding of SARS-CoV-2 infection throughout the intracellular viral life cycle are summarized and relate that to the knowledge of coronavirus biology.
Journal ArticleDOI

Drug repurposing approach to fight COVID-19.

TL;DR: The present review will focus on the repurposing efficacy of the currently used drugs against COVID-19 and their mechanisms of action, pharmacokinetics, dosing, safety, and their future perspective.
Journal ArticleDOI

COVID-19-associated coagulopathy and disseminated intravascular coagulation.

TL;DR: The pathology of coronavirus disease 2019 (COVID-19) is exacerbated by the progression of thrombosis, and disseminated intravascular coagulation (DIC), and cytokine storms, and its relationship with prognosis has been discussed.
References
More filters
Journal ArticleDOI

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.

SARS-CoV-2

Jeremy Luban
Journal ArticleDOI

Efficient Activation of the Severe Acute Respiratory Syndrome Coronavirus Spike Protein by the Transmembrane Protease TMPRSS2

TL;DR: This is the first report of TMPRSS2 being required in the target cell for activation of a viral fusion protein but not for the S protein synthesized in and transported to the surface of cells.
Related Papers (5)